Table 1.
Baseline patient and treatment characteristics.
| Variables | CFRT (n = 90) | MHRT (n = 90) | UHRT (n = 60) | p-value |
|---|---|---|---|---|
| Age (median, IQR) | 77 (71–80) | 75 (70–79) | 74 (68–79) | 0.1 |
| Risk group (n, %) UIR High risk |
0 90 (100 %) |
0 90 (100 %) |
13 (21.7 %) 47 (78.3 %) |
<0.0001 |
| Grade group (n, %) 1 2 3 4 5 Unknown |
0 14 (15.6 %) 10 (11.1 %) 33 (36.7 %) 29 (32.2 %) 4 (4.4 %) |
1 (1.1 %) 5 (5.6 %) 8 (8.9 %) 39 (43.3 %) 32 (35.6 %) 5 (5.6 %) |
1 (1.7 %) 10 (16.7 %) 15 (25 %) 18 (30 %) 16 (26.7 %) 0 (0 %) |
0.03 |
| Clinical stage (n, %) T1c T2a T2b T2c T3a T3b Unknown |
28 (31.1 %) 27 (30 %) 14 (15.6 %) 8 (8.9 %) 8 (8.9 %) 1 (1.1 %) 4 (4.4 %) |
30 (33.3 %) 23 (25.6 %) 12 (13.3 %) 7 (7.8 %) 12 (13.3 %) 1 (1.1 %) 5 (5.6 %) |
10 (16.7 %) 17 (28.3 %) 10 (16.7 %) 11 (18.3 %) 8 (13.3 %) 3 (5 %) 1 (1.7 %) |
0.3 |
| Baseline PSA (median, IQR) | 15.7 (7.1–26.5) | 13.5 (7.5–23.6) | 11.8 (6.9–19.9) | 0.3 |
| Baseline PSA categories (n, %) <10 10–20 >20 Unknown |
31 (34.4 %) 21 (23.3 %) 35 (38.9 %) 3 (3.3 %) |
30 (33.3 %) 27 (30 %) 29 (32.2 %) 4 (4.4 %) |
22 (36.7 %) 23 (38.3 %) 15 (25 %) 0 (0 %) |
0.3 |
| Risk of lymph node involvement (median, IQR) | 33.1 (10.4–73.7) | 32.9 (17.9–80.0) | 26.9 (21.7–33.0) | 0.0006 |
| Duration of ADT (median, IQR) | 22.2 (15–29.5) | 22 (15–30.1) | 12 (6.2–15.9) | <0.0001 |
| Duration of ADT categories (n, %) 0 months ≤12 months >12–24 months ≥24 months |
5 (5.6 %) 17 (18.9 %) 29 (32.2 %) 39 (43.3 %) |
3 (3.3 %) 15 (16.7 %) 35 (38.9 %) 37 (41.1 %) |
4 (6.6 %) 24 (40 %) 31 (51.7 %) 1 (1.7 %) |
<0.0001 |
*CFRT: conventionally fractionated radiotherapy; MHRT: moderately hypofractionated radiotherapy; UHRT: ultrahypofractionated radiotherapy; IQR: interquartile range; UIR: unfavorable intermediate risk; PSA: prostate specific antigen; ADT: androgen deprivation therapy.